The Lancet: Without immediate action nearly 260 million people in the USA predicted to have overweight or obesity by 2050
The Lancet
- Most comprehensive US analysis of overweight and obesity at the national level and across all states and age groups estimates that obesity rates in adults (aged 25 or older) and older adolescents (aged 15-24 years) have at least doubled over the past three decades (1990-2021).
- Southern states, including Oklahoma, Alabama, Arkansas, Mississippi, Texas, West Virginia, and Kentucky, had the highest levels of overweight and obesity among older adolescents (aged 15-24 years) in 2021—with over half of older adolescent males in Texas and nearly two-thirds of older adolescent females in Mississippi living with overweight or obesity.
- Without immediate action, the authors warn of an escalating crisis of overweight and obesity across the USA, with 213 million adults (over the age of 25) and more than 43 million children and adolescents (aged 5-24 years) expected to have overweight or obesity by 2050, with equally striking health, social, and economic consequences.
- With the prevalence of obesity projected to increase at a more rapid rate than overweight, by 2050, around one in five children, at least one in three adolescents and two in three adults are expected to have obesity—with the highest levels continuing to be concentrated in southern states.
- The authors say these findings underscore the urgent need for policy action focusing on population-level prevention and intervention, including legislative actions to promote access to healthy foods and improved regulation of the food, agricultural, and marketing sectors.
**For state-level data see figure 4A in paper and appendix 2**
Over the past three decades, there has been a startling increase in the prevalence of obesity across the USA, at least doubling in adult men and women (aged 25 and older) and older female and male adolescents (aged 15-24 years) since 1990, with the number of people living with overweight and obesity reaching over 208 million in 2021—a trend set to continue in the coming decades without significant reform, according to a major new analysis from the Global Burden of Disease Study Collaborator Network, published in The Lancet.
Especially high levels of overweight and obesity have already been reached in several US states, with over half (52%) of older adolescent males (aged 15-24 years) in Texas and nearly two-thirds (63%) of older adolescent females in Mississippi living with overweight or obesity in 2021. Similarly, in adults (aged 25 or older), around 80% of men in North Dakota and women in Mississippi were estimated to have overweight or obesity in 2021.
The study predicts devastating trends at the population level. The total number of US children and adolescents with overweight and obesity is expected to reach 43.1 million by 2050 (an additional 6.74 million from 2021), and the number of adults 213 million (an additional 41.4 million), underscoring the urgent need for concerted population-wide action to reverse these trends and the stark geographical and sex disparities.
“Our analysis lays bare the decades-long failure to tackle the growing overweight and obesity epidemic in the USA. The catastrophic consequences of the surge in overweight and obesity among children are already evident in the rising prevalence of childhood hypertension and type 2 diabetes,” said lead author Professor Emmanuela Gakidou from the Institute for Health Metrics and Evaluation (IHME), University of Washington, USA.
“Overweight and obesity can trigger serious health conditions—many of which are now occurring at younger ages, including diabetes, heart attacks, stroke, cancer, mental health disorders, and even premature death. The soaring health system and economic costs will be equally pervasive, with over 260 million people in the USA, including over half of all children and adolescents, expected to be living with overweight or obesity by 2050. United efforts and urgent investments are needed to alter these troubling trajectories and ensure a healthier future for current and upcoming generations.”
The new analysis estimated the prevalence of overweight and obesity for children and young adolescents (aged 5-14 years), older adolescents (aged 15-24 years), and adults (aged 25 and older) from 1990 to 2021 with forecasts to 2050 (assuming continuation of past trends and patterns) using 134 unique data sources, including all major national surveillance survey data. The new analysis provides in-depth forecasts, broken down at the state level, as well as by age and sex. Adjustments were made to correct for self-reporting bias.
For individuals older than 18 years, overweight was defined as having a BMI of 25 kg/m² to less than 30 kg/m² and obesity was defined as a BMI of 30 kg/m² or higher. For individuals younger than 18 years definitions were based on International Obesity Task Force criteria [1].
213 million American adults predicted to have overweight or obesity in 2050
Almost three-quarters of the adult population (172 million adults aged 25 or older) in the USA were estimated to be living with overweight or obesity in 2021. The prevalence of obesity rose especially rapidly, doubling between 1990 and 2021 in both adult men (from 18.6% to 41.5%) and women (from 22.8% to 45.6%; see table in Notes to Editors)
The estimated prevalence of adult overweight and obesity was high across all states in 2021. In men, levels ranged from 80.6% in North Dakota to 65.3% in Washington DC; while in women, levels ranged from 79.9% in Mississippi to 63.7% in Hawaii (see figures 1C and D in paper.)
Continuation of these trends would see overweight and obesity prevalence among adults (age-standardized to allow comparisons between states and over time) rise from an estimated 75.9% in 2021 to around 81.1% for men and from 72.6% to 82.1% for women. This would mean an estimated 41.4 million additional adults living with overweight or obesity by 2050 (raising the total to 213 million, of whom 146 million will have obesity).
Concerningly, the prevalence of obesity is projected to increase at a more rapid rate than overweight, and faster among adult men than women. Between 2021 and 2050, the highest rise in obesity prevalence among men is expected in Colorado (up 44.2%) and New Mexico (up 41.2%), and among adult women in Kansas and Colorado (both up 34.9%).
However, the highest levels of obesity are expected to remain in the southern states, with around two-thirds of adult men in West Virginia and Kentucky forecast to be living with obesity by 2050, as well as two-thirds of adult women in 12 states, with especially high rates of obesity predicted in Mississippi, West Virginia, and Arkansas and Alabama (both around 69%; see figure 4B in paper).
Interestingly, the onset of obesity has become earlier over subsequent generations. For example, approximately two out of five women born in the 1960s were living with obesity at the age of 45, however the same proportion were living with obesity by the age of 30 for women born in the 1980s, and by the age of 20 for women born in 2020 (see figure 5).
“Obesity is at a crisis point throughout the USA, with every state challenged to some degree,” said co-author Affiliate Associate Professor Marie Ng from IHME, University of Washington, USA. “Over the past three decades, the country has experienced extensive economic, demographic, and technological transitions that have triggered profound changes to food and agricultural systems, urbanisation, and wealth and educational inequalities together with underlying structural racism that all interact to drive population-wide obesity—whether it be the marketing of unhealthy food products to children, the proliferation of sedentary online activities, or food deserts (neighbourhoods that lack healthy, affordable food options) that are more common in racial and ethnic minority neighbourhoods.”
Unprecedented epidemic of childhood and adolescent obesity
The new analysis estimates that older adolescent obesity prevalence rose substantially in the USA between 1990 and 2021, more than doubling in both males (from 8.8% to 22.7%) and females (from 10.1% to 28.8% see table in Notes to Editors).
In 2021, an estimated 15.1 million children and young adolescents and 21.4 million older adolescents were living with overweight or obesity. However, they impact segments of the American population differently, with older adolescent females (50.8%) experiencing higher prevalence in 2021 than older adolescent males (46.7%), with especially high rates among older adolescent females in Mississippi, Alabama, and Oklahoma (where levels exceeded 59%), and among older adolescent males in Texas and West Virginia (where levels exceeded 52%; Figure 1A and B in paper).
The new study predicts that an additional 3.3 million children and young adolescents and 3.41 million older adolescents will be living with overweight or obesity by 2050 (raising the total to 43.1 million, of whom 24 million will have obesity).
With the increase in obesity projected to outpace the increase in overweight, around one in five children and at least one in three adolescents are expected to be living with obesity in 2050. The rising tide of adolescent obesity is projected to reach the highest levels among older adolescent males in Oklahoma (43%), Mississippi (39.8%) and West Virginia (37.7%) in 2050, and affect at least half of older adolescent females living in Mississippi, Arkansas, Oklahoma, and Alabama (see figure 4A). However, the largest numbers of older adolescents with obesity will continue to be in California (1.53 million) and Texas (1.49 million) in 2050.
Associate Professor Ng said: “The mechanisms behind the rising obesity prevalence are much more complex than just a matter of excessive energy intake and physical inactivity. Existing interventions which focus on lifestyle-based behavioural changes do not produce sufficient and sustainable reductions in overweight and obesity, especially among children and adolescents. Addressing the structural drivers of population obesity and emphasising prevention must be central to any future strategies. Future interventions also need to account for societal shifts in acceptance of obesity, alongside tailoring solutions by sex and for states with high obesity rates.”
Population-level prevention and a cross-government strategy key to tackling obesity crisis
The analysis notes that while anti-obesity medications like glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have a place in obesity management, they alone will not be enough to solve the obesity epidemic.
As Associate Professor Ng explains: “Given the predicted surge in overweight and obesity, demand for anti-obesity medication will definitely increase, but it is not a silver bullet. With concern surrounding prohibitive costs and equitable access, together with varying effectiveness and potentially serious side-effects, prevention will remain a primary strategy.”
The authors stress that prevention needs to become a much more dominant focus of obesity control and that any policies aiming to tackle the obesity crisis must be a priority at federal and state governments and backed by high-level political commitment. They should also be comprehensive, reaching individuals across the life course and targeting inequalities. For example, given that obesity is intergenerational, the authors say that intervention needs to begin with pregnant women and early feeding practices.
“Rather than relying on individual agency, stronger governance is needed to support and implement a multifaceted whole-system approach to radically disrupt the structural drivers of overweight and obesity at both national and community levels, as well as within households and schools,” said Professor Gakidou. “Federal policymakers must look beyond short-term political goals to target policy interventions not just within the health sector, for example ensuring all children have access to nutritious primary school meals and that there is greater regulation of junk food marketing.”
She added: “Above all, reversing the US obesity epidemic will rely on the government supporting programmes that increase levels of physical activity, such as investing in safe and walkable neighbourhoods, guaranteeing the availability of healthy food to children and adolescents, regulating the food and marketing industries, and achieving environmentally sustainable food systems.”
The authors note some important limitations, including that while the study uses the best available data, predictions are constrained by the quality and availability of data, and for that reason, they were unable to estimate the prevalence of childhood overweight and obesity at the state level. They also note that the definition of overweight and obesity is based on BMI, which might not account for variations in body structure across the population, and that they did not examine racial and ethnic disparities in obesity. Finally, past trends are not always predictive of what will happen in the future, and some factors, like the recent surge in the use of GLP-1 anti-obesity medications could alter the longer-term forecasting trends of overweight and obesity.
Writing in a linked Comment, Professor Syvain Sebert from the University of Oulu in Finland (who was not involved with the study) said: “A multifaceted, whole-system approach is needed to address the overweight and obesity crisis, with the challenge that it has now surpassed every known level of epidemic progression. Extensive collaboration is needed across all health sectors, and both public and personalised health approaches need to be combined to confront and address the challenge together. There is great hope in new therapeutic approaches, such as GLP-1 analogues, for more effective and well tolerated treatments for overweight and obesity; however, these treatments should not be seen as a reason to abandon prevention efforts. Health-care systems cannot manage the epidemic solely through life-long secondary prevention policies…Hopefully this excellent new report will find its way onto the global policy agenda to aid in prevention efforts for all causes identified and all potential consequences of the obesity crisis.”
NOTES TO EDITORS
The study was funded by the Bill & Melinda Gates Foundation. It was conducted by the GBD 2021 US Burden of Disease Collaborators.
Quotes from Authors cannot be found in the text of the Article, but have been supplied for the press release. The Comment quote is taken directly from the linked Comment.
[1] Extended international (IOTF) body mass index cut‐offs for thinness, overweight and obesity - Cole - 2012 - Pediatric Obesity - Wiley Online Library
US older adolescents overweight and obesity estimates and projections (1990, 2021, and 2050)
US older adolescents | 1990 | 2021 | 2050 |
Overweight and obesity prevalence males | 31.4% | 46.7% | 54.0% |
Overweight and obesity prevalence females | 26.0% | 50.8% | 60.8% |
Number males overweight or obesity | 6.1 million | 10.5 million | 11.9 million |
Number females overweight or obesity | 4.8 million | 10.9 million | 12.8 million |
Obesity prevalence males | 8.8% | 22.7% | 30.6% |
Obesity prevalence females | 10.1% | 28.8% | 38.0% |
US adults overweight and obesity estimates and projections (1990, 2021, and 2050)
US adults (25+ years) | 1990 | 2021 | 2050 |
Overweight and obesity prevalence males | 60.5% | 75.9% | 81.1% |
Overweight and obesity prevalence females | 49.1% | 72.6% | 82.1% |
Number males with overweight or obesity | 45.8 million | 85.0 million | 103.6 million |
Number females with overweight or obesity | 41.3 million | 86.6 million | 109.5 million |
Obesity prevalence males | 18.6% | 41.5% | 55.3% |
Obesity prevalence females | 22.8% | 45.6% | 58.8% |
The labels have been added to this press release as part of a project run by the Academy of Medical Sciences seeking to improve the communication of evidence. For more information, please see: http://www.sciencemediacentre.org/wp-content/uploads/2018/01/AMS-press-release-labelling-system-GUIDANCE.pdf if you have any questions or feedback, please contact The Lancet press office pressoffice@lancet.com
Journal
The Lancet
Method of Research
Computational simulation/modeling
Subject of Research
People
Article Title
National-level and state-level prevalence of overweight and obesity among children, adolescents, and adults in the USA, 1990–2021, and forecasts up to 2050
Article Publication Date
14-Nov-2024
COI Statement
A Al-Ibraheem reports grants or contracts and consulting fees from the International Atomic Energy Agency; participation on a Data Safety Monitoring Board or Advisory Board with the King Hussein Cancer Center; leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid, at the World Federation of Nuclear Medicine, Arab Society of Nuclear Medicine, and Jordanian Society of Nuclear Medicine; all outside the submitted work. T W Bärnighausen reports grants or contracts from National Institutes of Health (NIH), Alexander von Humboldt Foundation, German National Research Foundation (DFG), EU, German Ministry of Education and Research, German Ministry of the Environment, Wellcome, and KfW, all through payments to their institution; payment or honoraria for serving as Editor-in-Chief of PLoS Medicine; unpaid participation on Scientific Advisory Boards for two NIH-funded research projects in Africa on Climate Change and Health; stocks in CHEERS, a small-to-medium enterprise focusing on approaches to measure climate change and health-related variables in population cohorts; all outside the submitted work. S Bhaskar reports grants or contracts from Japan Society for the Promotion of Science (JSPS), Japanese Ministry of Education, Culture, Sports, Science and Technology (MEXT) through Grant-in-Aid for Scientific Research (KAKENHI), and from JSPS and the Australian Academy of Science through the JSPS International Fellowship; and leadership or fiduciary role, paid or unpaid, with National Cerebral and Cardiovascular Center (Suita, Osaka, Japan), Rotary District 9675 (Sydney, NSW, Australia), Global Health & Migration Hub Community, Global Health Hub Germany (Berlin, Germany), PLOS One, BMC Neurology, Frontiers in Neurology, Frontiers in Stroke, Frontiers in Aging, Frontiers in Public Health, and BMC Medical Research Methodology, College of Reviewers, Canadian Institutes of Health Research (CIHR), Government of Canada, Cardiff University Biobank (Cardiff, UK), and Cariplo Foundation (Milan, Italy); all outside the submitted work. E J Boyko reports payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from the Korean Diabetes Association, Diabetes Association of the ROC (Taiwan), American Diabetes Association, and International Society for the Diabetic Foot, all outside the submitted work. A Guha reports grants or contracts from the American Heart Association and the US Department of Defense; consulting fees from Pfizer and Novartis; and a leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid, with the ZERO Prostate Cancer Health Equity task force; all outside the submitted work. M S Khan reports consulting fees from Bayer outside the submitted work. M Lee reports support for their participation in the present manuscript from the Ministry of Education of the Republic of Korea and the National Research Foundation of Korea (NRF-2023S1A3A2A05095298). S A Meo reports grants or contracts from the Deputyship for Research and Innovation, Ministry of Education in Saudi Arabia (IFKSUOR3-4-10) outside the submitted work. N Scarmeas reports grants or contracts from Novo Nordisk through funding to their institution; participation on a Data Safety Monitoring Board or Advisory Board with the Multicultural Healthy Diet to Reduce Cognitive Decline & AD Risk Safety Monitoring Board and with Primus AD Data Safety Monitoring Board; all outside the submitted work. J A Singh reports consulting fees from ROMTech, Atheneum, Clearview healthcare partners, American College of Rheumatology, Yale, Hulio, Horizon Pharmaceuticals, DINORA, ANI/Exeltis, USA, Frictionless Solutions, Schipher, Crealta/Horizon, Medisys, Fidia, PK Med, Two labs, Adept Field Solutions, Clinical Care options, Putnam associates, Focus forward, Navigant consulting, Spherix, MedIQ, Jupiter Life Science, UBM, Trio Health, Medscape, WebMD, and Practice Point communications and the NIH; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from the speakers bureau of Simply Speaking; support for attending meetings from OMERACT; participation on a Data Safety Monitoring Board or Advisory Board with the US Food and Drug Administration (FDA) Arthritis Advisory Committee; leadership or fiduciary role in other board, society, committee or advocacy group, paid, as a past steering committee member of the OMERACT, and unpaid as Chair of the Veterans Affairs Rheumatology Field Advisory Committee and as the Editor and Director of the UAB Cochrane Musculoskeletal Group Satellite Center on Network Meta-analysis; stock or stock options in Atai life sciences, Kintara Therapeutics, Intelligent Biosolutions, Acumen Pharmaceutical, TPT Global Tech, Vaxart Pharmaceuticals, Atyu Biopharma, Adaptimmune Therapeutics, GeoVax Labs, Pieris Pharmaceuticals, Enzolytics, Seres Therapeutics, Tonix Pharmaceuticals Holding, Aebona Pharmaceuticals, and Charlotte’s Web Holdings; and previously owned stock options in Amarin, Viking, and Moderna Pharmaceuticals; all outside the submitted work. D Trico reports payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from AstraZeneca, Eli Lilly, and Novo Nordisk; support for attending meetings or travel from AstraZeneca, Eli Lilly, and Novo Nordisk; participation on a Data Safety Monitoring Board or Advisory Board with Amarin; and receipt of equipment, materials, drugs, medical writing, gifts or other services through their institution from PharmaNutra and Abbott; all outside the submitted work. M Zielińska reports other financial or non-financial interests in AstraZeneca as an employee, outside the submitted work.
